About The Study: Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in forced vital capacity from baseline to week 48.
About The Study: Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in forced vital capacity from baseline to week 48.
Quote from corresponding author, Ganesh Raghu, M.D.:
“Current treatment with the two drugs approved by regulatory agencies for the treatment of idiopathic pulmonary fibrosis (IPF) merely slow the rate of lung function decline and are associated with adverse events that affect medication adherence. Because of the high mortality rates that are associated with IPF, the need for efficacious treatments that meaningfully improve patients’ feeling and function, as well as survival, is evident and unmet.
“This well-conducted, multinational phase 3 trial undertaken to assess the efficacy and safety of pamrevlumab for patients with IPF failed to confirm it. Despite the disappointment with the negative results, the success lies in the patients who participated in this trial and adhered to the protocol amid all the challenges and hurdles of the COVID-19 pandemic and lessons gleaned will help better design of future trials.”
Contact information for Ganesh Raghu, M.D.: email graghu@uw.edu.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.8693)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Thoracic Society 2024 International Conference.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
Discover more from Science
Subscribe to get the latest posts sent to your email.
